Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Multiple Myeloma 6Recurrence 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Blast Crisis 2Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Rhabdoid Tumor 1

Interventions

pembrolizumab 29Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × Panobinostat × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡